Literature DB >> 19787337

Motivational effects of opiates in conditioned place preference and aversion paradigm--a study in three inbred strains of mice.

Wojciech Solecki1, Anna Turek, Jakub Kubik, Ryszard Przewlocki.   

Abstract

RATIONALE: Interstrain differences in the motivational properties of morphine and heroin have been previously reported in mice, suggesting the involvement of a genotype-dependent modulation of the rewarding effects of opiates. Yet, interstrain differences in the motivational effects of naloxone have not been described.
OBJECTIVES: The aim of our study was to examine genotype modulation of the motivational effects of opiates in inbred stains of mice with known, distinct, opiate-induced phenotypes, and morphine-induced striatal transcriptional responses.
METHODS: We studied the rewarding properties of morphine (5, 10, and 20 mg/kg i.p.) and heroin (1, 5, and 10 mg/kg i.p.) in conditioned place preference (CPP) as well as the aversive properties of naloxone (1, 10, and 20 mg/kg i.p.) in the conditioned place aversion (CPA) paradigm in C57Bl/6J (C57), DBA/2J (DBA), and SWR/J (SWR) inbred strains of mice.
RESULTS: Our results show that morphine and heroin as well as naloxone induce CPP and CPA, respectively, in a genotype- and dose-dependent manner in these studied inbred strains of mice. Interestingly, C57 mice are the most sensitive in the case of the rewarding properties of morphine and heroin but are the least sensitive to the aversive effects of naloxone, whereas the DBA strain exhibit the opposite behavioral effects.
CONCLUSIONS: We suggest that motivational homeostasis can be modulated by mu opioid receptors in mice, with the C57 mice representing a genotype that is more sensitive to processes related to rewards, whereas the genotype of DBA is more sensitive to aversion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787337     DOI: 10.1007/s00213-009-1672-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  55 in total

Review 1.  Psychopharmacology of dopamine: the contribution of comparative studies in inbred strains of mice.

Authors:  S Puglisi-Allegra; S Cabib
Journal:  Prog Neurobiol       Date:  1997-04       Impact factor: 11.685

2.  The difference in stress-induced analgesia in C57BL/6 and DBA/2 mice: a search for biochemical correlates.

Authors:  B Przewłocka; J Vetulani; W Lasoń; M Dziedzicka; J Silberring; C Castellano; R Przewłocki
Journal:  Pol J Pharmacol Pharm       Date:  1988 Sep-Oct

3.  Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphin.

Authors:  R F Mucha; M J Millan; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles.

Authors:  A L Svingos; C Chavkin; E E Colago; V M Pickel
Journal:  Synapse       Date:  2001-12-01       Impact factor: 2.562

Review 5.  Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies.

Authors:  J N Crawley; J K Belknap; A Collins; J C Crabbe; W Frankel; N Henderson; R J Hitzemann; S C Maxson; L L Miner; A J Silva; J M Wehner; A Wynshaw-Boris; R Paylor
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

6.  In vivo evidence that genetic background controls impulse-dependent dopamine release induced by amphetamine in the nucleus accumbens.

Authors:  Rossella Ventura; Antonio Alcaro; Laura Mandolesi; Stefano Puglisi-Allegra
Journal:  J Neurochem       Date:  2004-04       Impact factor: 5.372

7.  Heroin-induced locomotor activity and conditioned place preference in C57BL/6J and 129P3/J mice.

Authors:  Stefan D Schlussman; Yong Zhang; Nicole M Hsu; Julia M Allen; Ann Ho; Mary Jeanne Kreek
Journal:  Neurosci Lett       Date:  2008-06-04       Impact factor: 3.046

8.  Dopamine in the medial prefrontal cortex controls genotype-dependent effects of amphetamine on mesoaccumbens dopamine release and locomotion.

Authors:  Rossella Ventura; Antonio Alcaro; Simona Cabib; Davide Conversi; Laura Mandolesi; Stefano Puglisi-Allegra
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

9.  Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats.

Authors:  P Rada; G P Mark; E Pothos; B G Hoebel
Journal:  Neuropharmacology       Date:  1991-10       Impact factor: 5.250

10.  Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists.

Authors:  Sheri D Grabus; Billy R Martin; Sharon E Brown; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2006-02-04       Impact factor: 4.530

View more
  19 in total

1.  Hippocampal long-term potentiation is disrupted during expression and extinction but is restored after reinstatement of morphine place preference.

Authors:  George S Portugal; Ream Al-Hasani; Amanda K Fakira; Jose L Gonzalez-Romero; Zare Melyan; Jordan G McCall; Michael R Bruchas; Jose A Morón
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

2.  Role of nucleus accumbens μ opioid receptors in the effects of morphine on ERK1/2 phosphorylation.

Authors:  Michela Rosas; Simona Porru; Sandro Fenu; Stefania Ruiu; Alessandra T Peana; Alessandro Papale; Riccardo Brambilla; Gaetano Di Chiara; Elio Acquas
Journal:  Psychopharmacology (Berl)       Date:  2016-05-31       Impact factor: 4.530

3.  Strain difference in the effect of infralimbic cortex lesions on fear extinction in rats.

Authors:  Chun-hui Chang; Stephen Maren
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

4.  Increased morphine analgesia and reduced side effects in mice lacking the tac1 gene.

Authors:  A Bilkei-Gorzo; J Berner; J Zimmermann; R Wickström; I Racz; A Zimmer
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity.

Authors:  Agnieszka Gieryk; Barbara Ziolkowska; Wojciech Solecki; Jakub Kubik; Ryszard Przewlocki
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

6.  Regional mRNA expression of the endogenous opioid and dopaminergic systems in brains of C57BL/6J and 129P3/J mice: strain and heroin effects.

Authors:  S D Schlussman; J Cassin; Y Zhang; O Levran; A Ho; M J Kreek
Journal:  Pharmacol Biochem Behav       Date:  2011-07-23       Impact factor: 3.533

7.  Short-Term Genetic Selection for Adolescent Locomotor Sensitivity to Delta9-Tetrahydrocannabinol (THC).

Authors:  Chelsea R Kasten; Yanping Zhang; Ken Mackie; Stephen L Boehm
Journal:  Behav Genet       Date:  2018-03-17       Impact factor: 2.805

8.  The dissection of transcriptional modules regulated by various drugs of abuse in the mouse striatum.

Authors:  Marcin Piechota; Michal Korostynski; Wojciech Solecki; Agnieszka Gieryk; Michal Slezak; Wiktor Bilecki; Barbara Ziolkowska; Elzbieta Kostrzewa; Iwona Cymerman; Lukasz Swiech; Jacek Jaworski; Ryszard Przewlocki
Journal:  Genome Biol       Date:  2010-05-04       Impact factor: 13.583

9.  Double-dissociation of D1 and opioid receptor antagonism effects on the acquisition of sucrose-conditioned flavor preferences in BALB/c and SWR mice.

Authors:  Cheryl T Dym; Tamar T Kraft; Veronica S Bae; Yakov Yakubov; Khalid Touzani; Anthony Sclafani; Richard J Bodnar
Journal:  Pharmacol Biochem Behav       Date:  2012-08-07       Impact factor: 3.533

10.  Distinct Subpopulations of Nucleus Accumbens Dynorphin Neurons Drive Aversion and Reward.

Authors:  Ream Al-Hasani; Jordan G McCall; Gunchul Shin; Adrian M Gomez; Gavin P Schmitz; Julio M Bernardi; Chang-O Pyo; Sung Il Park; Catherine M Marcinkiewcz; Nicole A Crowley; Michael J Krashes; Bradford B Lowell; Thomas L Kash; John A Rogers; Michael R Bruchas
Journal:  Neuron       Date:  2015-09-02       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.